Evidence map›Paper›PMID 37854093›Full record

ArticleFrontiers in tropical diseases2022

Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits.

Irina Tretyakova, Mark Tomai, John Vasilakos, Peter Pushko

Open access · goldAbstract read
In one paragraph

Article in Frontiers in tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. mSphere · 2025
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Irina TretyakovaMedigen, Inc., Frederick, MD, United States.
Mark Tomai3M Company, St. Paul, MN, United States.
John VasilakosKindeva Drug Delivery, St. Paul, MN, United States.
Peter PushkoMedigen, Inc., Frederick, MD, United States.
Medigen (United States) · US3M (United States) · USKindeva Drug Delivery (United States) · US

Funding

Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase IIR44AI094863 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2016 to 2017
$1.6M
Novel DNA-Launched Attenuated Vaccine for VEE VirusR43AI094863 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2011 to 2012
$600k
Novel Chikungunya vaccine with rearranged genomeR43AI152717 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2020 to 2021
$241k
NIAID NIH HHS R43 AI094863NIAID NIH HHS R43 AI152717NIAID NIH HHS R44 AI094863
6 · The paper itself

Abstract

Effective and simple delivery of DNA vaccines remains a key to successful clinical applications. Previously, we developed a novel class of DNA vaccines, sometimes called iDNA, which encodes the whole live-attenuated vaccine viruses. Compared to a standard DNA vaccine, an iDNA vaccine required a low dose to launch a live-attenuated vaccine

Indexed as

DNA vaccineiDNAlive-attenuated vaccinemicroneedleTC83V4020VEEVenezuelan equine encephalitis virus

Identifiers

PMID37854093
PMCPMC10583749
OpenAlexW4220998641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.